Home The top biopharmaceutical deals of 2014
 

Keywords :   


The top biopharmaceutical deals of 2014

2014-12-15 16:30:41| Biotech - Topix.net

In January, Teva made an unsolicited offer to buy NuPathe Inc. of Malvern, Pa., for $114 million - topping a $105 million offer Endo International put in play at the end of 2013. Teva ultimately bought NuPathe, the developer of the migraine headache treatment Zecuity, for $144 billion in February.

Tags: top deals deals top biopharmaceutical

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
28.09Atlantic Tropical Weather Outlook
28.09Eastern North Pacific Tropical Weather Outlook
28.09Hurricane Isaac Forecast Discussion Number 9
28.09Post-Tropical Cyclone Helene Graphics
28.09Post-Tropical Cyclone Helene Public Advisory Number 19
28.09Tropical Storm Joyce Graphics
28.09Hurricane Isaac Graphics
28.09Hurricane Isaac Wind Speed Probabilities Number 9
More »